Elevated Capital Advisors LLC Buys 1,761 Shares of Amgen Inc. $AMGN

Elevated Capital Advisors LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 146.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,960 shares of the medical research company’s stock after acquiring an additional 1,761 shares during the period. Elevated Capital Advisors LLC’s holdings in Amgen were worth $1,042,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Roman Butler Fullerton & Co. increased its stake in shares of Amgen by 2.3% during the first quarter. Roman Butler Fullerton & Co. now owns 1,929 shares of the medical research company’s stock worth $675,000 after purchasing an additional 43 shares during the period. Range Financial Group LLC lifted its holdings in Amgen by 5.9% during the 1st quarter. Range Financial Group LLC now owns 12,568 shares of the medical research company’s stock worth $4,422,000 after purchasing an additional 699 shares during the last quarter. Meadow Creek Wealth Advisors LLC boosted its stake in Amgen by 14.9% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 2,122 shares of the medical research company’s stock valued at $747,000 after purchasing an additional 275 shares during the period. Forza Wealth Management LLC boosted its stake in Amgen by 1.1% in the 1st quarter. Forza Wealth Management LLC now owns 7,018 shares of the medical research company’s stock valued at $2,469,000 after purchasing an additional 76 shares during the period. Finally, First Horizon Corp grew its holdings in Amgen by 27.3% in the 1st quarter. First Horizon Corp now owns 64,675 shares of the medical research company’s stock valued at $22,756,000 after buying an additional 13,857 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $363.62 on Friday. The firm has a 50 day moving average of $344.30 and a 200-day moving average of $349.22. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market capitalization of $196.25 billion, a PE ratio of 25.30, a PEG ratio of 3.63 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMGN. BMO Capital Markets restated an “outperform” rating and issued a $400.00 price target on shares of Amgen in a research note on Wednesday, July 1st. UBS Group lifted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Truist Financial boosted their price objective on shares of Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a report on Tuesday. Piper Sandler restated an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Finally, Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $355.73.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.